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Immunizing  animals  in  the  wild  against  Brucella  (B.) 
abortus is essential to control bovine brucellosis because 
cattle can get the disease through close contact with infected 
wildlife. The aim of this experiment was to evaluate the 
effectiveness  of  the  B.  abortus  strain  RB51  vaccine  in 
protecting  infection  as  well  as  vertical  transmission  in 
Sprague-Dawley  (SD)  rats  against  B.  abortus  biotype  1. 
Virgin female SD rats (n = 48) two months of age were divided 
into two groups: one group (n = 24) received RB51 vaccine 
intraperitoneally with 3 ×  10
10 colony forming units (CFU) 
and the other group (n = 24) was used as non-vaccinated 
control.  Non-vaccinated  and  RB51-vaccinated  rats  were 
challenged with 1.5 × 10
9 CFU of virulent B. abortus biotype 
1 six weeks after vaccination. Three weeks after challenge, all 
rats  were  bred.  Verification  of  RB51-vaccine  induced 
protection in SD rats was determined by bacteriological, 
serological and molecular screening of maternal and fetal 
tissues  at  necropsy.  The  RB51  vaccine  elicited  81.25% 
protection in SD rats against infection with B. abortus biotype 
1. Offspring from rats vaccinated with RB51 had a decreased 
(p ＜ 0.05) prevalence of vertical transmission of B. abortus 
biotype 1 compared to the offspring from non-vaccinated 
rats (20.23% and 87.50%, respectively). This is the first 
report  of  RB51  vaccination  efficacy  against  the  vertical 
transmission of B. abortus in the SD rat model.
Keywords: Bruce-ladder multiplex PCR assay, brucellosis, 
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Introduction 
Brucellosis is an economically important zoonotic 
disease that affects animals and humans. It is caused by the 
facultative intracellular bacteria belonged to the genus 
Brucella [23]. In most host species, the disease primarily 
affects the reproductive system [9], with major clinical 
manifestation of brucellosis in wildlife and cattle being 
abortion, decreased fertility, and placenta retention [27, 
35]. Brucellosis has been known to exist in wildlife 
populations [10]. Wild rats are known to harbor Brucella 
organisms [17,36] and have found to be infected with 
Brucella (B.) abortus on farms where cattle were infected 
[17]. In Siberia and the Far East, gray rats were found to be 
a carrier of brucellosis [19]. The occurrence of disease in 
humans is largely dependent on the occurrence of 
brucellosis in wildlife reservoirs [12].
The transmission of B. abortus from dam to offspring has 
also been well documented in rats, mice, and cattle [2-4]. 
Vertical infection among offspring born to infected dams 
constitutes a major problem in eradication of brucellosis 
[34]. Successful eradication programs of brucellosis 
requires the elimination of brucellosis from the primary 
reservoir of the disease as well as free ranging wildlife, 
development of intervention measures against congenital 
brucellosis, use of efficacious vaccine and implementation 
of biosecurity measures [2,10,26].
B. abortus strain RB51 is widely used as a vaccine against 
bovine brucellosis in many countries, including the USA, 
in addition to the “test and slaughter” policy for the 
eradication of brucellosis in cattle [28]. RB51 is a stable 
rough mutant derived from the standard virulent B. abortus 
strain 2308 [28] and research data suggests that it induces 
protection in bison and cattle against abortion or infection 
with virulent B. abortus strains [20-22]. Our previous 
study had demonstrated vertical transmission of B. abortus 
biotype 1 in Sprague-Dawley (SD) rats [2]. In this study we 
verified the protective capacity of RB51 vaccine in the SD 
rats against infection as well as vertical transmission of the 
virulent B. abortus biotype 1 Korean bovine isolate.
Materials and Methods
Experimental rats
Virgin female (n = 48) and male (n = 8) SD rats of 2 months 212    Md. Ariful Islam et al.
of age, weighing 200∼250 g were used for this experiment. 
The parent stocks of male and female rats were purchased 
from a government-licensed laboratory animal company 
(Koatech, Korea) which was bred to produce sufficient 
number of rats for use in this experiment. The rats were 
housed in a stringently hygienic, climate- controlled 
environment and supplied with commercial feed and water 
ad libitum. All experiments were carried out in compliance 
with the humane protocols approved by the Chonbuk 
National University, Jeonju, Korea under the supervision of 
veterinarians. The animals were culture negative for 
Brucella  infection and seronegative for B. abortus 
antibodies, prior to the experimental infection, ascertained 
by routine bacteriological and serological tests.
Vaccination and challenge of rats
Female virgin rats (n = 48) were divided into two groups: 
vaccinated group and non-vaccinated control group. The 
rats (n = 24) of the vaccinated group were injected 
intraperitoneally with 0.1 mL of physiological saline 
containing 3 × 10
10 CFU of the B. abortus strain RB51 
vaccine. The non-vaccinated control rats (n = 24) were 
injected intraperitoneally with 0.1 mL of sterile physiological 
saline solution. Both groups were challenged 6 weeks after 
vaccination with the virulent strain of B. abortus biotype 1 
by an intraperitoneal injection of 1.5 × 10
9 CFU in 0.1 mL 
of normal saline. A master seed stock of RB51 was 
obtained from the Colorado Serum Company (USA). 
Before inoculation, the vaccine or challenge bacteria were 
cultured on brucella agar media (Difco, USA) for 7 days at 
37
oC with 5% CO2. 
Clinical examinations
All of the SD rats in our experiment were clinically 
examined after vaccination with RB51 or challenged with 
virulent B. abortus biotype 1. Rectal temperatures were 
recorded daily for the first week and the rats were observed 
twice daily for the duration of the study for adverse 
reactions or clinical signs such as anorexia, lethargy and 
anaphylaxis resulted from the vaccination or challenge.
Breeding of rats
Three weeks after challenge, RB51-vaccinated (n = 16) 
and non-vaccinated control (n = 16) female rats were 
simultaneously bred with healthy male SD rats at the ratio 
of 1 : 4 (1 male for 4 females). One male and four females 
were kept in a single cage for one month. Pregnant dams 
were placed in individual cages 3∼4 days before 
parturition. After parturition the number of live or stillborn 
offspring/dam and weight of day-old live offspring were 
recorded. 
Collection of tissues
Prior to the challenge and breeding, four randomly 
selected rats in RB51-vaccinated and non-vaccinated 
control groups were anesthetized by intraperitoneal 
administration of 15 mg/kg of tiletamine and zolazepam 
(Zoletil 50; Virbac Laboratories, France) and blood 
samples were collected by aseptic cardiac puncture. 
Necropsy of RB51-vaccinated and non-vaccinated rats 
were performed at 10 weeks after challenge with B. 
abortus biotype 1. Blood samples were collected from 
RB51-vaccinated and non-vaccinated parturient and 
non-pregnant rats under general anesthesia. The rats were 
then euthanized and spleen, liver, kidney, lung and uteri 
were collected. Day-old offspring of RB51-vaccinated and 
non-vaccinated rats were euthanized and spleen, liver and 
lung were collected. Serum samples were stored at −80
oC 
until tested. All other samples were stored at −20
oC until 
cultured. 
Bacteriologic studies
All tissue samples were thawed. The tissue sample was 
macerated separately in a stomacher (IUL Instruments, 
Spain). Each of the macerated tissue samples was cultured 
in duplicate in blood agar media (Becton, Dickinson and 
Company, USA) and brucella agar media (Difco, USA) 
supplemented with antibiotics [Cycloheximide (100 
mg/L), Polymixin B (25,000 IU/L), and Bacitracin (6,000 
IU/L) that inhibit growth of bacteria other than Brucella] 
and incubated at 37
oC with 5% CO2 for 7 days. The 
identification of the isolates in the culture positive 
specimens was conducted by routine methods as described 
previously [1,28].
Polymerase chain reaction
Bacteria harvested from culture positive specimens of 
rats were confirmed to be B. abortus biotype 1 by 
Bruce-ladder multiplex polymerase chain reaction (PCR) 
as described previously [16]. For Bruce-ladder multiplex 
PCR profiling, DNA was extracted from Brucella 
suspected colonies by a genomic DNA extraction kit 
(AccuPrep DNA Extraction Kit; Bioneer, Korea) using the 
manufacturer’s protocol.
Serum antibody responses
Thawed serum samples were screened for antibody to B. 
abortus biotype 1 by the Rose Bengal plate agglutination 
test (RBPAT) and standard tube agglutination test according 
to the previously described methods [1]. The total IgG, 
IgG1 and IgG2a titers in the sera of RB51-vaccinated and 
non-vaccinated control rats 3 weeks post challenge or at 
necropsy were measured by ELISA using smooth 
lipopolysaccharide (LPS) of B. abortus biotype 1. The LPS 
was extracted from the B. abortus biotype 1 by a 
commercial LPS extraction kit (Intron Biotechnology, 
Korea) using manufacturer’s protocol. Flat-bottomed 
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Table 1. Pregnancy rate, litter size, offspring body weight and 
survival data in RB51-vaccinated and non-vaccinated rats 
challenged with Brucella (B.) abortus biotype 1
RB51- Non- 
Parameters vaccinated vaccinated p value
rats (n = 16) rats (n = 16)
No. of pregnant or parturient  16 (100) 9 (56.25) ND
 rats (%)
No. of infertile rats (%) 0 (0) 7 (43.75) ND
Total number of offspring* 184 89 ND
Mean no. of  11.50 ± 1.31  9.88 ± 1.45  ＜0.05
 offspring/litter* (range) (8∼13) (7∼12)
No. of stillborn offspring (%) 0 (0) 15 (16.85) ND
No. of live offspring (%) 184 (100) 74 (83.15) ND
Mean offspring weight† (g) 6.93 ± 0.32 6.22 ± 0.31 ＜0.001
*Live and stillborn offspring only. 
†Live offspring only. ND, not 
determined. 
were coated with 100 μL of LPS (5 μg/mL) of B. abortus 
biotype 1 suspended in 0.05 mM sodium bicarbonate 
buffer (pH 9.6). Affinity purified rat IgG, IgG1 and IgG2a 
(Bethyl Laboratories, USA) were used to coat the 96-well 
plate starting from 500 ng/well to 7.8 ng/well to generate 
the standard curve. Each plate was incubated at 4
oC 
overnight. Plates were washed three times with wash 
solution [PBST: PBS (pH 7.4) with 0.05% (v/v) Tween 
20]. Each well of the antigen-coated plates were blocked 
with 200 μL of blocking solution of 1% (w/v) bovine serum 
albumin (Sigma Aldrich, USA) in PBS and incubated at 
37
oC for 30 min. Then the plates were washed three times 
with PBST. Each sample of sera was diluted 1 : 100 in 
sample diluent (50 mM tris, 0.14 M Nacl, 1% BSA, 0.05% 
Tween 20, pH 8.0) and 100 μL of diluted serum was added 
to duplicate wells of a 96-wells plate. The plates were 
sealed and incubated at 37
oC for 1 h. After five washing 
cycles with PBST, each well was incubated with 100 μL of 
1 : 100,000 dilution of goat anti-rat IgG, IgG1 and IgG2a 
antibodies conjugated to horseradish peroxidase (Bethyl 
Laboratories, USA) diluted in conjugate diluent (50 mM 
tris, 0.14 M Nacl, 1% BSA, 0.05% Tween 20, pH 8.0), and 
the plates incubated at 37
oC for 1 h. After five washings as 
described above, the color reaction was developed by 
adding 200 μL/well of a solution containing 1.0 mg/mL of 
O-phenylenediamine dihydrochloride (OPD; Sigma, USA) 
in 0.05 M citrate buffer (pH 4.0) with 0.04% (v/v) H2O2. 
The plates were incubated in the dark for 30 min at room 
temperature then the colorimetric reaction was stopped by 
the addition of 50 μL/well of 3 M H2SO4. The absorbance 
measurements were made at 492 nm, using an automatic 
ELISA plate reader (Tecan, Austria). 
Statistical analysis
The arithmetic means of offspring number, offspring 
weight and antibody titers between RB51-vaccinated and 
non-vaccinated control groups were compared for 
statistical significance by Student’s t-test (Excel; Microsoft, 
USA). Chi-square analysis was used to compare vertical 
transmission rates between RB51-vaccinated and non- 
vaccinated control rats (Excel; Microsoft, USA). Significance 
of all the analyses was established at a p value of ＜ 0.05.
Results
Clinical signs
The rectal temperature of rats after vaccination with B. 
abortus strain RB51 was within normal range (35∼36
oC). 
After challenge with virulent B. abortus, the non- 
vaccinated rats developed a fever, became lethargic and 
developed anorectic conditions within 24 h and the rectal 
temperature rose to 38
oC within 72 h. None of the RB51- 
vaccinated rats after virulent challenge manifested any 
abnormal clinical signs. 
Pregnancy  rate,  litter  size,  offspring  weight  and 
survival data
Significant protection against B. abortus infection was 
observed in RB51-vaccinated rats. All of the RB51- 
vaccinated rats (n = 16) became pregnant in spite of being 
intraperitoneally challenged with a field strain of B. 
abortus. On the other hand, 9 of 16 non-vaccinated 
challenged rats were pregnant. RB51-vaccinated rats 
delivered 184 live offspring while the 9 pregnant non- 
vaccinated control rats delivered 74 live and 15 stillborn 
offspring. No stillbirths were found in the RB51-vaccinated 
challenged rats. The average body weight of the day-old 
live offspring was 6.93 ± 0.32 g in RB51-vaccinated rats 
and 6.22 ± 0.31 g in non-vaccinated rats. The average litter 
size was 11.50 ± 1.31 for RB51-vaccinated rats and 9.88 ± 
1.45 for non-vaccinated rats. Fertility rate was very low in 
non-vaccinated rats in comparison to RB51-vaccinated 
rats. The pregnancy rate, litter size, offspring weight and 
survival data are presented in Table 1.
Dam and offspring infections
Dam or offspring infection was defined as the recovery of 
the B. abortus biotype 1 challenge strain from any maternal 
or offspring sample. The B. abortus biotype 1 was 
recovered from several tissues at necropsy, though the 
recovery of B. abortus from samples was greater in the 
non-vaccinated group than the RB51-vaccinated group. 
The result of B. abortus biotype 1 recovery from necropsy 
samples is shown in Table 2.
All isolates recovered from the RB51-vaccinated and 
non-vaccinated challenged rats and offspring at necropsy 
were identified as smooth B. abortus by routine bacteriolo-214    Md. Ariful Islam et al.
Fig. 1. Bruce-ladder multiplex PCR assay. Lane 1: DNA 
molecular weight standard marker; Lane 2: bacterial DNA of 
non-vaccinated rat; Lane 3: bacterial DNA of RB51-vaccinated 
rat; Lane 4: bacterial DNA of offspring born to non-vaccinated 
dam; Lane 5: bacterial DNA of offspring born to RB51- 
vaccinated dam; Lane 6: positive control with DNA of Brucella
(B.) abortus strain 1119-3; Lane 7: positive control with DNA of 
B. abortus strain RB51; Lane 8: negative control without DNA.
Table 3. Results of B. abortus isolation and identification from RB51-vaccinated and non-vaccinated rats and offspring at necropsy by
routine bacteriological methods and Bruce-ladder multiplex PCR assay
  No. of isolates confirmed as 
No. of culture  No. of culture negative
Group (No. of animals) B. abortus biotype 1 by Bruce-
positive rats (%) rats (%)
ladder multiplex PCR assay
RB51-vaccinated female rats (16)  3 (18.75) 13 (81.25) 3
Non-vaccinated female rats (16) 16 (100) 0 (0) 16
Offspring born to RB51-vaccinated dams (184) 23 (12.50) 161 (87.50) 23
Offspring born to non-vaccinated dams (89) 71 (79.77) 18 (20.23) 71
Table 2. Recovery of B. abortus from RB51-vaccinated, non- 
vaccinated rats and offspring at necropsy 
RB51-vaccinated Non-vaccinated
Pregnant
16
Pregnant Non-pregnant 
97
Maternal
Spleen 3/16 9/9 7/7
Liver 2/16 9/9 7/7
Kidney 2/16 9/9 7/7
Lungs 0/16 7/9 7/7
Uterus 2/16 7/9 7/7
Offspring
Spleen 23/184 71/89
Liver 10/184 71/89
Lungs 6/184 60/89
Overall
Maternal 3/16 9/9 7/7
Offspring 23/184 71/89
Results presented as number of B. abortus biotype 1 culture positive
samples/number of rats examined.
gical methods such as crystal violet staining of the 
colonies, acriflavin agglutination, agglutination to anti- 
Brucella smooth and rough sera and biochemical tests 
(catalase, oxidase, nitrate reduction, urease). None of the 
isolates were identified as B. abortus strain RB51. All 
positive cultured bacterial colonies harvested from specimens 
of RB51-vaccinated and non-vaccinated female rats as 
well as offspring at necropsy were also confirmed as B. 
abortus biotype 1 by Bruce-ladder multiplex PCR assay 
with the predicted 1,682, 794, 587, 450 and 152-bp sized 
PCR amplicons (Fig. 1). 
The  B. abortus isolation rate was lower in RB51- 
vaccinated rats compared to non-vaccinated control 
female rats. At necropsy, all (n = 16) of the non-vaccinated 
challenged rats (100%) were culture positive to B. abortus. 
On the other hand, only 3 of 16 RB51-vaccinated challenged 
rats (18.75%) were culture positive to B. abortus. The rate 
of fetal infection or vertical transmission of B. abortus 
among offspring was significantly lower in RB51- 
vaccinated rats (12.50%) compared to the offspring born to 
non-vaccinated rats (79.77%) (p  ＜ 0.05). The overall 
results of bacterial isolation and identification from the 
RB51-vaccinated and non-vaccinated female SD rats and 
their offspring at necropsy are shown in Table 3.
Antibody responses in RB51-vaccinated and non- 
vaccinated rats
Sera of four randomly selected rats in the RB51- 
vaccinated and non-vaccinated groups were seronegative 
prior to challenge by RBPAT, standard tube agglutination 
test and ELISA. On the day of breeding (3 weeks post- 
challenge), sera of four randomly selected rats from the 
RB51-vaccinated and non-vaccinated groups showed 
anti-B. abortus antibody responses in RBPAT, tube 
agglutination test and ELISA. The RB51-vaccinated rats 
had significantly lower (p  ＜  0.05) standard tube 
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Fig. 2. Standard tube agglutination titers of rats 3 weeks after 
challenge with B. abortus biotype 1 and at necropsy. Antibody 
titers are reported as mean ± SE. Statistically significant 
differences among RB51-vaccinated, non-vaccinated pregnant 
and non-pregnant control rats are indicated by asterisks (*p ＜
0.05 and †p ＜ 0.001).
Fig. 3. Total serum IgG, IgG1 and IgG2a levels of non-vaccinated control and RB51-vaccinated rats 3 weeks after challenge with B.
abortus biotype 1 (A) and at necropsy (B). Antibody titers are reported as mean ± SE. Statistically significant difference among 
RB51-vaccinated, non-vaccinated pregnant and non-pregnant control rats are indicated by asterisks (*p ＜ 0.05 and †p ＜ 0.001).
compared to non-vaccinated rats (Fig. 2). At necropsy, 3 of 
16 RB51-vaccinated rats were seroconverted according to 
RBPAT, standard tube agglutination test and ELISA. All 
rats in the non-vaccinated group showed B. abortus 
specific antibody responses at necropsy and pregnant rats 
in this group had lower (p  ＜  0.05) standard tube 
agglutination titers (314 ± 26) when compared to the 
non-pregnant rats (411 ± 11). The RB51-vaccinated rats 
had significantly lower (p  ＜  0.001) standard tube 
agglutination titers (83 ± 14) when compared to 
non-vaccinated rats at necropsy (Fig. 2). Our ELISA data 
also showed significantly lower (p ＜ 0.001) IgG, IgG1 
and IgG2a titers in the sera of RB51-vaccinated rats 
compared to non-vaccinated control rats at 3 weeks post 
challenge or at necropsy (Fig. 3).
When antibody responses against LPS of B. abortus 
biotype 1 were evaluated by ELISA, total serum IgG, IgG1 
and IgG2a titers were significantly lower (p ＜ 0.001) in 
RB51-vaccinated rats (878 ± 13, 154 ± 3 and 185 ± 2 
ng/mL, respectively) as compared to non-vaccinated 
control rats (1033 ± 16, 197 ± 3 and 242 ± 4 ng/mL, 
respectively) at 3 weeks after challenge with B. abortus 
biotype 1 (Fig. 3A).
At necropsy, total serum IgG, IgG1 and IgG2a titers 
measured by ELISA were significantly lower (p ＜ 0.001) 
in RB51-vaccinated pregnant rats (509 ± 2, 35 ± 5 and 104 ± 
0.2 ng/mL, respectively) in comparison to non-vaccinated 
control pregnant (1,284 ± 12, 324 ± 6 and 267 ± 2 ng/mL, 
respectively) and non-pregnant rats (1,320 ± 10, 357 ± 3 
and 284 ± 2 ng/mL, respectively) (Fig. 3B).
Discussion
Brucellosis has been emerging as a serious animal and 
public health problem in many parts of the world [8], 
including Korea [24], despite animal control and eradication 
programs. Control of brucellosis in animals is essential for 
its control in humans [13]. The current brucellosis control 
programs in many parts of the world, including Korea, are 
based on test and slaughter of sero-positive cattle [33]. If 
the slaughter of infected herds is limited to sero-positive 
adult animals, the latently infected calves could be a source 
of infection to the new farm [15]. Another likely source for 
reintroduction of brucellosis into livestock is from infected 
populations of free-ranging wildlife [10]. To control 
bovine brucellosis in endemic areas, the wild animals need 
to be free from brucellosis. Congenital infection caused by 
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in the epizootiology of brucellosis [2,34] as eradication of 
brucellosis could not be achieved without preventing 
vertical transmission. The need to develop intervention 
measures against congenital brucellosis in wild and 
domesticated animals prompted us to evaluate the RB51 
vaccine on the protection of infection and vertical 
transmission against B. abortus biotype 1 in a SD rat model.
It is well established in the literature that brucellosis 
protection is measured by a significant decrease in 
abortions or birth of weak offspring, and a significant 
decrease in colonization of vaccinated animals when 
compared to non-vaccinated animal control after challenge 
[11]. The data of this study demonstrated that the 
pregnancy rate was higher in RB51-vaccinated rats (100%) 
compared with non-vaccinated rats (56.25%), and the 
mean litter size was also significantly higher in RB51- 
vaccinated rats (11.50 ± 1.31) in comparison to the 
non-vaccinated rats (9.88 ± 1.45) (p ＞ 0.05). In addition, 
the mean weight of day-old live offspring was significantly 
higher in RB51-vaccinated rats (6.93 ± 0.32) compare to 
non-vaccinated rats (6.22 ± 0.31) (p < 0.001). B. abortus 
causes loss in productivity of animals by abortion, 
infertility, decrease in milk production and birth of weak 
and dead calves through reproductive tract infection [9]. In 
this study, 2 of 16 (12.5%) uteri of RB51-vaccinated 
pregnant rats and 7 of 9 (77.78%) non-vaccinated pregnant 
rats were found to be infected with B. abortus 10 weeks 
after challenge. The significant difference of pregnancy 
rate, litter size and weight of offspring between RB51- 
vaccinated and non-vaccinated rats in our studies indicated 
that RB51-vaccine elicited significant protection against 
infection in vaccinated rats when compared to non- 
vaccinated rats.
Our study demonstrated that RB51-vaccine protected 
81.25% of female rats against Brucella  infection and 
proteced 87.50% of offspring against the vertical transmission 
of  B. abortus. Some studies have reported that RB51 
vaccine protected 87% of inoculated heifers against 
infection and protected 70% of calves against congenital 
infection after experimental challenged with virulent B. 
abortus [6,26].
The isolation of the challenge strain from different 
specimens was used as the criterion for brucellosis 
infection, as it is widely recognized to be the most 
definitive criterion for measuring the effect of brucella 
vaccination [26]. In the current study, isolation of B. 
abortus biotype 1 was performed from the spleen, liver, 
kidney, lung and uterus, as these are most frequently 
infected tissue in B. abortus infected animals [7]. At 
necropsy, we recorded a low level of persistence of B. 
abortus in the maternal tissues of RB51-vaccinated rats 
(18.75%) compared to the non-vaccinated rat (100%). 
Localization of B. abortus was primarily recorded in the 
lymphoid and uterine tissues of the non-vaccinated rat. 
Results of our bacteriological data suggest that vaccination 
with RB51 was efficacious in preventing intrauterine and 
fetal infection following exposure to virulent strain of B. 
abortus.
　In vaccine trials, the dosages and strains of B. abortus 
that are used for challenge are important. An ideal situation 
is obtained when over 99% of challenge controls become 
infected [18]. In the present study, all of the non-vaccinated 
control rats were found to be infected with B. abortus 
biotype 1 following experimental challenge with 1.5 × 10
9 
CFU of B. abortus biotype 1.
The results of serology using RBPAT, standard tube 
agglutination test and ELISA were negative from the day 
of vaccination through the day of challenge confirming the 
absence of serological interference from RB51 vaccination 
with the serological diagnostic tests for bovine brucellosis. 
The antibody response in smooth B. abortus is directed 
against LPS O-antigen, which could be detected by 
serological tests [5,7,29,31]. The lack of antibody response 
in RB51 vaccinates is most likely due to the absence of 
O-antigen [5,7,28,29]. After challenging with B. abortus 
biotype 1 all rats gave positive results in the serological 
tests used in this study. 
Reports of vaccination in mice and cattle with RB51 
indicate that it does not induce protective antibody 
responses against B. abortus strain 2308 [14,30,32]. Our 
serological tests did not detect antibody responses induced 
by strain RB51 6 weeks after vaccination. Antibody 
responses in the present study were detected only after 
challenge with B. abortus biotype 1. Serological data in 
this study showed low antibody titers in the RB51- 
vaccinated rats compared to non-vaccinated rats following 
challenge with B. abortus biotype 1. The low recovery rate 
of B. abortus biotype 1 in the vaccinated rats might have 
been responsible for the reduction of sero-converted 
antibody titers in RB51-vaccinated rats compared to non- 
vaccinated rats. Bison vaccinated with RB51 also showed 
lower standard tube agglutination titers as compared to 
non-vaccinated control following an experimental challenge 
with B. abortus 2308 [21]. In mice, RB51 vaccine caused 
no increase of antibody titers over non-vaccinated control 
following a challenge with B. abortus 2308 [14].
In this study, the difference of antibody titers between 
RB51-vaccinated and non-vaccinated rats was greater at 
10 weeks compared to 3 weeks after challenge, which 
might have resulted from the induction of enhanced 
resistance of RB51 vaccine against B. abortus at 10 weeks 
compared to 3 weeks after challenge. Previous studies 
reported that RB51 vaccines induces enhanced resistance 
against B. abortus in mice at 7 weeks and in cattle between 
10 and 12 weeks after vaccination [28,31].
Cell mediated immune (CMI) response is important in 
clearing the infection caused by the intracellular bacteria 
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response in cattle [31], and mice were reported to be 
protected by RB51 vaccine against B. abortus 2308 
through CMI response [14,32]. The RB51 vaccine in mice 
and bison significantly reduced the recovery of virulent B. 
abortus  2308 compared to non-vaccinated controls 
[14,21]. In our study, B. abortus isolation rate was lower in 
the RB51-vaccinated group compared to the non- 
vaccinated control group, suggesting that the RB51 
vaccine in SD rats might have played an important role for 
the intracellular killing of challenged bacteria in various 
organs (spleen, liver, kidney, lung and uterus) through CMI 
response. 
In the current study, we chose the intraperitoneal route for 
inoculation of B. abortus biotype 1 to determine the effect 
of this route on vertical transmission as well as reproductive 
functions of SD rats. Our present study demonstrated 
vertical transmission as well as reproductive disorders in 
SD rat, while our previous study recorded only vertical 
transmission in SD rats when inoculated with B. abortus 
subcutaneously [2]. We vaccinated SD rats with RB51 
through the intraperitoneal route because other studies 
showed that this route confers the best protection in mice 
against B. abortus compared to subcutaneous and oral 
routes [14,25]. Under field conditions, the intraperitoneal 
route may not be a good option for vaccinating wildlife. 
Further studies are required for the development of an 
effective vaccine delivery system for free ranging wildlife 
under field conditions. Our data suggests that the RB51 
vaccine is effective in protecting SD rats against infection 
and vertical transmission of B. abortus. Therefore, RB51 
vaccine would be beneficial in reducing the prevalence of 
B. abortus in the wild rat to facilitate eradication of 
brucellosis in humans and animals.
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